PDR Network introduces RxEvent, a new online network to collect and distribute adverse drug events now available to all US prescribers via integration into electronic health record platforms and other online services, including directly at www.RxEvent.org.
Roughly half a million adverse drug events are reported annually to the FDA, with over 90 percent of these reports coming from pharmaceutical manufacturers who receive them from physicians and other providers via telephone. This legacy call center-based system is expensive for manufacturers and inconvenient and time-consuming by physicians; it is not surprising that studies show as few as one in ten ADEs are actually reported by healthcare professionals due to this cumbersome process. RxEvent addresses this issue by offering physicians a new way to report ADEs quickly and easily from within their workflow to improve the quality, timeliness, and overall reporting of adverse events.
RxEvent benefits include:
· Decreasing costs associated with current call centers and backend manual processing and reporting;
· Improving reporting quality and rates by physicians and pharmacists by placing the system within their workflow;
· Increasing data mining value through report customization and electronic data gathering; and
· Allowing for monitoring of off-label use and new side effects developing with approved use.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.